Early clinical experience with vericiguat after acute decompensated heart failure in elderly patients with HFrEF: a prospective observational study

Vericiguat has demonstrated clinical benefit in patients with heart failure with reduced ejection fraction (HFrEF), particularly in those at high risk of recurrent heart failure events. However, evidence regarding its early use in elderly patients following hospitalization for acute decompensated HF (ADHF) remains limited. In this prospective single-center case series, 143 consecutive patients aged > 70 years hospitalized for ADHF with HFrEF were enrolled and vericiguat was administrated. Clinical evaluations, left ventricular ejection fraction (LVEF), six-minute walk test (6MWT), Minnesota Living with Heart Failure Questionnaire (MLHFQ), and laboratory parameters were assessed at baseline and after 4 weeks. After 4 weeks of treatment with vericiguat, 44.8% of patients were in NYHA class II and 55.2% in NYHA class III, no patients were in NYHA class IV (p < 0.001); LVEF improved from 34 ± 4.7% to 46.8 ± 7.5% (p < 0.0001); exercise capacity increased significantly (p < 0.001), while a significant decrease in MLHF-Q, NT-proBNP levels and hsCRP was observed (p < 0.001). No symptomatic hypotension, syncope or relevant deterioration in renal function or electrolytes occurred during the observation period. In this single-arm cohort of older patients with HFrEF recently stabilized after ADHF, initiation of vericiguat was feasible and coincided with substantial short-term changes in functional status, LVEF, and circulating biomarkers, without major safety signals during 4 weeks of observation. Given the absence of a control group, these changes cannot be attributed to vericiguat and may reflect, at least in part, recovery from the acute event, decongestion, optimization of background therapy, learning effects, and regression to the mean. These findings should therefore be considered descriptive and hypothesis-generating and require confirmation in controlled studies.

Authors

Institutions

Publication Details

Journal
Internal and Emergency Medicine
Published
2026-11-13
DOI
https://doi.org/10.1007/s11739-026-04588-4
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Early clinical experience with vericiguat after acute decompensated heart failure in elderly patients with HFrEF: a prospective observational study

Paolo Calabrò, Giuseppe Caporaso, Vincenzo Provitera, Giuseppe Rengo et al.
6 links
Internal and Emergency Medicine
Heart Failure Treatment and Management
article

Early clinical experience with vericiguat after acute decompensated heart failure in elderly patients with HFrEF: a prospective observational study

Paolo Calabrò, Giuseppe Caporaso, Vincenzo Provitera, Giuseppe Rengo, Raffaele Antonelli Incalzi, Chiara Acanfora, Klara Komici, Gerardo Casucci, Gennaro Galasso, Domenico Acanfora
article en

Abstract

Vericiguat has demonstrated clinical benefit in patients with heart failure with reduced ejection fraction (HFrEF), particularly in those at high risk of recurrent heart failure events. However, evidence regarding its early use in elderly patients following hospitalization for acute decompensated HF (ADHF) remains limited. In this prospective single-center case series, 143 consecutive patients aged > 70 years hospitalized for ADHF with HFrEF were enrolled and vericiguat was administrated. Clinical evaluations, left ventricular ejection fraction (LVEF), six-minute walk test (6MWT), Minnesota Living with Heart Failure Questionnaire (MLHFQ), and laboratory parameters were assessed at baseline and after 4 weeks. After 4 weeks of treatment with vericiguat, 44.8% of patients were in NYHA class II and 55.2% in NYHA class III, no patients were in NYHA class IV (p < 0.001); LVEF improved from 34 ± 4.7% to 46.8 ± 7.5% (p < 0.0001); exercise capacity increased significantly (p < 0.001), while a significant decrease in MLHF-Q, NT-proBNP levels and hsCRP was observed (p < 0.001). No symptomatic hypotension, syncope or relevant deterioration in renal function or electrolytes occurred during the observation period. In this single-arm cohort of older patients with HFrEF recently stabilized after ADHF, initiation of vericiguat was feasible and coincided with substantial short-term changes in functional status, LVEF, and circulating biomarkers, without major safety signals during 4 weeks of observation. Given the absence of a control group, these changes cannot be attributed to vericiguat and may reflect, at least in part, recovery from the acute event, decongestion, optimization of background therapy, learning effects, and regression to the mean. These findings should therefore be considered descriptive and hypothesis-generating and require confirmation in controlled studies.

Internal and Emergency Medicine
University of Molise (IT), University of Salerno (IT), Università Campus Bio-Medico (IT), Istituti Clinici Scientifici Maugeri (IT), University of Campania "Luigi Vanvitelli" (IT), Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona (IT), Campus Bio Medico University Hospital (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), University of Naples Federico II (IT)
Good health and well-being
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon